CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B Feb 7, 2025 09:12AM
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People L Dec 11, 2023 07:30PM
CSL and uniQure Win 2023 Prix Galien USA Award Oct 27, 2023 10:00AM
CSL Behring Announces the First Patient Has Received FDA-Approved HEMGENIX® (etranacogene dezaparvovec-drlb) for Hemophilia B Jun 20, 2023 07:00AM
CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb) Feb 23, 2023 08:00AM


Feb 20, 2023 04:42PM First Gene Therapy for Hemophilia B, CSL's HEMGENIX®, Approved by the European Commission
Dec 10, 2022 10:00AM CSL's Novel Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates Durable Protection and Sustained Factor IX Activity Levels for People Living with Hemophilia B at 24-Months Post-Treat
Nov 22, 2022 03:59PM U.S. Food and Drug Administration approves CSL's HEMGENIX® (etranacogene dezaparvovec-drlb), the first gene therapy for hemophilia B
Nov 2, 2022 06:30PM Next-Generation mRNA, Gene Therapy, Plasma Products, Monoclonal Antibodies, and Recent Acquisitions and Collaborations Highlight CSL R&D Day 2022
May 24, 2022 08:00AM FDA Accepts CSL Behring's Biologics License Application for Etranacogene Dezaparvovec for Priority Review
Mar 28, 2022 02:13AM European Medicines Agency Commences Review of Novel Gene Therapy Candidate Etranacogene Dezaparvovec for People with Hemophilia B
Feb 4, 2022 10:20AM Final Analysis of Pivotal HOPE-B Study Demonstrates Durable and Sustained Therapeutic Effect of Etranacogene Dezaparvovec Gene Therapy in Hemophilia B - Data Presented at EAHAD 2022
Dec 15, 2021 07:33AM CSL Behring Receives Accelerated CHMP Assessment for Etranacogene Dezaparvovec for European Patients Living with Hemophilia B
Dec 9, 2021 07:07AM uniQure (QURE), CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
Dec 9, 2021 07:05AM uniQure and CSL Behring Announce Primary Endpoint Achieved in HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B
May 6, 2021 07:05AM CSL Behring Announces Closing of Global Commercialization and License Agreement with uniQure for etranacogene dezaparvovec
Jun 24, 2020 06:28PM CSL Behring Agrees to Acquire Novel Late-Stage Gene Therapy Candidate for Hemophilia B Patients from uniQure
Jan 16, 2020 11:10AM UPDATE: Axalta (AXTA) Viewed as Most Likely Takeover Target in Survey of M&A Desks - Bloomberg
Sep 21, 2015 05:25PM Market Wrap: Tsipras Reelected as Greek PM; Apple Car Chatter Heats up; Clinton Takes Aim at Biotechs
Apr 6, 2015 07:32AM Bristol-Myers Squibb and uniQure Enter into Exclusive Strategic Collaboration to Develop Gene Therapies for Cardiovascular Diseases